Condition: Asthma · Sponsor: National Jewish Health
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.
This description comes directly from the study's public registry record.
Michael Wechsler, MD · 303-398-1443 · wechslerm@njhealth.org
Juno Pak · 303-398-1132 · pakj@njhealth.org
Always discuss trial participation with your own doctor first.
| National Jewish Health | Denver, Colorado, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02947945